On December 3, 2025 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 as well as highlights from its recent webinar. The clinical trial demonstrated encouraging durable disease control in 63 heavily pre-treated patients with advanced solid tumors, many of which had DNA damage repair (DDR) pathway deficiencies. The clinical trial met all primary endpoints for safety, tolerability, and established a clear recommended phase 2 dose (RP2D).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Building on these encouraging Phase 1a results, Lantern is advancing an ambitious precision oncology development strategy featuring multiple biomarker‑guided Phase 1b/2 clinical trials in triple‑negative breast cancer (TNBC), glioblastoma multiforme (GBM), non‑small cell lung cancer (NSCLC), and advanced urothelial carcinoma (bladder cancer). The company and independent industry analysts estimate that the aggregate annual market opportunity for LP‑184 across these and additional targeted indications could exceed $10 billion.

KEY HIGHLIGHTS:

Phase 1a Trial Successfully Completed with Encouraging Efficacy Signals: 63 heavily pre-treated patients (median 3+ prior therapies) with advanced solid tumors enrolled; trial achieved 54% disease control rate in patients at or above therapeutic dose levels, demonstrating promising activity in DNA damage repair-deficient cancers
Exceptional Durability in Difficult-to-Treat Cancers: Patients with stage 4 squamous lung cancer (BRCA1 mutation), thymic carcinoma (CHEK2 mutation), and gastrointestinal stromal tumor (ATM mutation) remain on treatment with 12+ to 23+ months of ongoing clinical benefit and meaningful tumor reductions after failing multiple prior therapies.
Addresses Major Market Opportunity in Precision Oncology: LP-184 targets the estimated 20-25% of solid tumor patients with DDR deficiencies—representing more than 400,000 cases annually and a market potential exceeding $10 billion in annual drug sales.
AI-Driven Biomarker Strategy Strengthened: Lantern’s RADR platform identified PTGR1 as a key predictive biomarker; >87% of Phase 1a patients (recurrent, advanced solid tumors) exceeded the bioactivation threshold, with a diagnostic-ready molecular assay enabling patient selection and/or stratification.
Strong Regulatory Support Accelerates Development: Five FDA designations (3 Orphan Drug, 2 Fast Track) for LP-184 across TNBC, GBM, pancreatic cancer, and rare pediatric tumors provide development advantages and potential expedited pathways to approval.
Multi-Indication Phase 1b/2 Program Are Advancing: Biomarker-guided trials are being planned and advancing in markets with high patient need: triple-negative breast cancer (monotherapy + PARP inhibitor combination); drug and IO resistant, PDL-1 low, non-small cell lung cancer (NSCLC); recurrent glioblastoma (GBM) ( with +spironolactone); and advanced recurrent DDR deficient bladder cancer.
PHASE 1A CLINICAL HIGHLIGHTS

The Phase 1a study enrolled 63 patients with advanced solid tumors who had received a median of three prior lines of therapy. Key findings include:

Established Recommended Phase 2 Dose (RP2D): 0.39 mg/kg administered intravenously on Days 1 and 8 of a 21-day cycle
Favorable Safety Profile: Main adverse events included reversible transaminitis, nausea/vomiting, and thrombocytopenia—all clinically manageable and consistent with the alkylating agent class
High Therapeutic Index: Therapeutic plasma concentrations achieved three dose levels below RP2D, indicating a wide therapeutic window (~2.45-fold)
Encouraging Disease Control: 54% disease control rate and 8% clinical benefit rate at ≥6 months in DDR-altered tumors
Biomarker Validation: More than 87% of Phase 1a patients exceeded the PTGR1 bioactivation threshold, confirming the biomarker’s utility for patient selection
REMARKABLE PATIENT DURABILITY SIGNALS CLINICAL POTENTIAL

Several patients with DDR pathway alterations in the Phase 1a study achieved exceptional, ongoing responses despite having progressed through multiple prior standard-of-care therapies:

A 62-year-old male patient with stage 4 squamous NSCLC harboring a BRCA1 alteration, who had failed radiation and durvalumab, began LP-184 treatment in December 2023 and continues on therapy with more than 23 months of clinical benefit (Cycle 34 ongoing) and 22% target lesion reduction
A 50-year-old male patient with stage 4 thymic carcinoma with a CHEK2 alteration, who had progressed through four prior lines including pembrolizumab, started LP-184 in November 2023 and remains on treatment with more than 12 months of benefit (Cycle 17 ongoing) and 26% target lesion reduction
A 62-year-old female patient with stage 4 gastrointestinal stromal tumor (GIST) harboring an ATM alteration, who had failed four prior therapies including sunitinib, initiated LP-184 in November 2023 and continues treatment with more than 12 months of benefit (Cycle 19 ongoing) and 9% tumor reduction
These durability signals in heavily pre-treated, genomically-defined patient populations underscore LP-184’s potential as a precision oncology therapy and support the company’s biomarker-driven development strategy.

AI-GUIDED PRECISION MEDICINE APPROACH

Lantern’s proprietary RADR artificial intelligence platform played a central role in LP-184’s development, identifying prostaglandin reductase-1 (PTGR1) overexpression and low expression of multiple DDR genes as strong predictors of LP-184 sensitivity.

LP-184 functions as a prodrug that is selectively activated inside cancer cells by PTGR1, which is frequently overexpressed in tumors. Upon activation, LP-184 forms a highly reactive metabolite that breaks apart the DNA of the cancer cell and induces interstrand cross-links and double-strand breaks—damage that cannot be repaired in tumors with deficient DDR pathways, resulting in selective cancer-cell death while sparing normal cells.

Critically, LP-184 demonstrates activity across both homologous recombination (HR)-deficient and nucleotide excision repair (NER)-deficient tumors, potentially addressing a broader patient population than PARP inhibitors, which primarily target HR deficiency. Preclinical data show LP-184 is active even in PARP inhibitor-resistant models, highlighting its differentiated mechanism.

Lantern has developed a diagnostic-ready RT-qPCR assay for PTGR1 expression in FFPE tumor tissue, enabling patient selection for ongoing and future trials consistent with a precision oncology approach.

REGULATORY MOMENTUM SUPPORTS ACCELERATED DEVELOPMENT

LP-184 has received six FDA designations recognizing its potential to address serious unmet medical needs:

Fast Track Designation for triple-negative breast cancer (TNBC)
Fast Track Designation for glioblastoma multiforme (GBM) (granted October 2024)
Orphan Drug Designation for malignant gliomas
Orphan Drug Designation for pancreatic cancer
Orphan & Pediatric Rare Disease Drug Designation for atypical teratoid rhabdoid tumors (ATRT)
These designations provide significant regulatory and development advantages, including more frequent interactions with the FDA, rolling submission of New Drug Application (NDA) sections, and potential eligibility for Accelerated Approval and Priority Review—mechanisms designed to expedite patient access to promising therapies in areas of high unmet need.

AMBITIOUS MULTI-INDICATION DEVELOPMENT PROGRAM IN DEVELOPMENT & UNDERWAY

Building on the Phase 1a foundation, Lantern has initiated and is planning to initiate and enroll multiple biomarker-guided Phase 1b/2 trials and investigator-sponsored studies:

Triple-Negative Breast Cancer (TNBC): Monotherapy and LP-184 plus olaparib (PARP inhibitor) combination arms in HR-deficient TNBC patients (n≈60-64 total). TNBC represents approximately 15% of all breast cancers with limited targeted therapy options and poor prognosis in the metastatic setting.
Advanced Drug-Resistant, Non-Small Cell Lung Cancer (NSCLC): LP-184 plus nivolumab and ipilimumab (dual checkpoint inhibitors) in patients with KEAP1/STK11 mutations and PD-L1 <50% (n≈34)—a genomically-defined subset with poor response to immunotherapy and chemotherapy alone.
Advanced Urothelial Carcinoma: LP-184 monotherapy investigator-sponsored trial in Denmark in patients with PTGR1-high expression and NER/HR pathway deficiencies (n≈27-39).
Recurrent Glioblastoma (GBM): LP-184 plus spironolactone combination (n≈38-39), targeting the first potential new GBM therapy in more than 20 years. GBM affects more than 13,000 U.S. patients annually with median survival of 12-15 months and virtually no effective options at recurrence. Trial initiation expected in early 2025 under the wholly owned subsidiary, Starlight Therapeutics.
Lantern is also reviewing additional development opportunities beyond these core Phase 1b/2 programs. Post-radiation pancreatic cancer represents a particularly compelling indication, as radiation therapy has been shown to upregulate tumoral PTGR1 expression, potentially enhancing LP-184’s tumor-selective activation. The company is also further exploring optimized dosing schedules to maximize therapeutic impact in certain solid tumors.

MANAGEMENT COMMENTARY

The trial met all primary endpoints for safety and tolerability and established a clear Recommended Phase 2 Dose with a wide therapeutic window.

"These are patients who had exhausted standard options, yet several remain on LP-184 with meaningful clinical benefit in challenging cancers one to two years later," said Panna Sharma, CEO of Lantern Pharma. "This durability in genomically selected, end-stage cancer patients is encouraging and directly validates the predictive power of our RADR AI platform and the PTGR1 biomarker. With a diagnostic-ready molecular assay for PTGR1, strong enthusiasm from key opinion leaders and multiple FDA designations in hand, Lantern plans on advancing LP-184 into multiple precision Phase 1b/2 trials targeting indications with aggregate annual U.S. market potential exceeding $10 to 12 billion."

WEBINAR: INSIDE THE DATA, AN IN-DEPTH DISCUSSION OF THE LP-184 SCIENCE, CLINICAL TRIAL RESULTS, AND FUTURE DEVELOPMENT PLANS

For a comprehensive review of LP-184’s mechanism of action, detailed Phase 1a clinical data, patient case studies, and the company’s development strategy, Lantern Pharma invites stakeholders to view the recent "Inside The Data" webinar featuring management and a Key Opinion Leader from Fox Chase Cancer Center. The webinar provides in-depth scientific context and clinical insights that complement this announcement and is available on Lantern Pharma’s YouTube channel at: View Source

About LP-184

LP-184 is a next-generation acylfulvene that is synthetically lethal and designed to selectively target solid tumors with DNA damage repair pathway deficiencies. As a prodrug activated by the enzyme PTGR1, LP-184 induces irreparable DNA damage in cancer cells while sparing normal tissue. The compound has demonstrated nanomolar potency in preclinical models and encouraging durability in clinical studies in heavily pre-treated patients. LP-184 has received FDA Fast Track Designation for TNBC and GBM, and Orphan Drug Designation for malignant gliomas, pancreatic cancer, and ATRT.

(Press release, Lantern Pharma, DEC 3, 2025, View Source [SID1234661111])

On December 3, 2025 Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported that the patients in the first cohort have been dosed in its Phase 1 trial evaluating STRO-004 in a range of Tissue Factor (TF) expressing solid tumors. STRO-004 is the Company’s TF-targeting exatecan ADC engineered for best-in-class stability, potency, and tumor selectivity using Sutro’s proprietary cell-free platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dosing the initial patients in this trial marks an important milestone in bringing forward new treatment options for patients with TF–expressing cancers—many of whom face limited therapy options and difficult prognoses. We’ve seen strong engagement from our clinical investigators, who recognize the potential of STRO-004 to address a pressing need in oncology—and we’re proud of the speed and precision with which our team brought the program into the clinic," said Jane Chung, Chief Executive Officer of Sutro Biopharma. "STRO-004 is engineered to deliver potent, sustained anti-tumor activity and higher exposure compared to approved therapies, with the goal of reaching tumors that are resistant to standard approaches. Through this trial, we aim to generate early insights into safety and activity that will guide development in areas of urgent unmet need. We are deeply grateful to the patients and investigators participating in this study and look forward to sharing initial data in mid-2026."

The Phase 1 open-label, multicenter trial is designed to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-004 in patients with advanced TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and bladder cancer. The dose-escalation phase includes multiple cohorts with ascending dose levels, supported by strong tolerability in non-human primates at up to 50 mg/kg. Sutro’s design enables high entry doses, with the goal of rapidly identifying a recommended Phase 2 dose and early signs of clinical activity.

More information can be found at: View Source

About STRO-004
STRO-004 is a next-generation antibody-drug conjugate (ADC) targeting tissue factor (TF), a clinically validated tumor-associated antigen expressed across multiple solid tumors. In preclinical studies, STRO-004 demonstrated robust anti-tumor activity, favorable tolerability, and higher exposure compared to approved therapies. Developed using Sutro Biopharma’s proprietary cell-free platform, STRO-004 features an Fc-silent, high affinity antibody, with site-specific β-glucuronidase cleavable linker and exatecan payload at a drug-to-antibody ratio of 8 (DAR8). This design aims to enhance stability, reduce off-target toxicity, and maximize efficacy. It is currently being evaluated in a Phase 1 trial in patients with a range of TF-expressing solid tumors.

(Press release, Sutro Biopharma, DEC 3, 2025, https://ir.sutrobio.com/news-events/news-releases/detail/224/sutro-biopharma-announces-first-cohort-of-patients-dosed-in-phase-1-trial-of-stro-004-a-next-generation-tissue-factor-adc-in-tf-expressing-solid-tumors [SID1234661110])

On December 3, 2025 Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano reported new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003, the company’s intravenous (IV) Deciparticle formulation of everolimus, substantially reduces gastrointestinal (GI) drug accumulation, addressing one of the most significant and well-recognized limitations of oral everolimus (Afinitor). The data indicate that Sapu003 may offer improved tolerability while preserving the drug’s intrinsic metabolic profile and enabling more consistent systemic exposure.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IV Sapu003 Reduces GI Exposure to Everolimus by 67-Fold Compared With Oral Dosing

New tissue-distribution data show that Sapu003, delivered intravenously, eliminates the extreme gastrointestinal accumulation characteristic of oral everolimus. After oral dosing, everolimus reaches 2,448× plasma levels in the stomach, 750× plasma in the small intestine, and 323× plasma in the large intestine, confirming that the gut is the dominant exposure site for the oral formulation.

In contrast, IV Sapu003 demonstrates only 36-48× plasma levels across the same GI tissues, representing a 67-fold reduction in stomach exposure, a 15.7-fold reduction in small-intestinal exposure, and a 7.4-fold reduction in large-intestinal exposure.

These findings provide a clear mechanistic explanation for the well-documented GI toxicity of oral everolimus-including stomatitis, mucositis, abdominal discomfort, and diarrhea.

Presentation information: PS4-06-05. Sapu003: Everolimus for Injection – Pharmacokinetic Rationale for Phase I Evaluation in HR /HER2 Metastatic Breast Cancer. Wen-Han Chang, John Lopp, Sheng-Hao Min, Robert Hoff, Nancy Chang, Tanjina Hoque, Ann Park, and Cynthia Lee.

Potential for Improved Clinical Tolerability and Antitumor Potency

By bypassing the gastrointestinal tract and delivering the drug directly into circulation, Sapu003:

Avoids the high local GI concentrations associated with oral toxicity
Produces more consistent systemic exposure
Enhances drug penetration into tumor-relevant tissues

These PK advantages complement previously reported efficacy findings in which Sapu003 achieved 97-98% tumor inhibition in glycolysis-addicted xenograft while outperforming paclitaxel.

Management Commentary

"The fundamental challenge with oral everolimus is that the majority of the drug ends up in the gut, leading directly to the GI toxicity that limits its use," said Dr. Cynthia Lee, VP of R&D. "These new data show that IV Sapu003 avoids that problem entirely. By reducing GI accumulation by up to 67-fold, Sapu003 has the potential to offer a far more tolerable and clinically versatile version of everolimus."

About Sapu003

Sapu003 is a novel intravenous nanoparticle formulation of everolimus engineered using Sapu Nano’s proprietary Deciparticle technology. It is designed to overcome the poor bioavailability, intestinal toxicity, and variable patient exposure seen with oral everolimus while enabling reliable, predictable weekly IV dosing.

About the Deciparticle Platform

The Deciparticle platform is a proprietary nanotechnology engineered to encapsulate hydrophobic molecules as uniform, sub-20 nm nanoparticles for intravenous administration. The platform improves systemic exposure, reduces GI deposition, and supports precision delivery while maintaining manufacturability at clinical scale.

(Press release, Oncotelic, DEC 3, 2025, View Source [SID1234661109])

On December 3, 2025 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, reported updated interim data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) non-muscle invasive bladder cancer (NMIBC). These results in Bacillus Calmette-Guérin (BCG)-Naïve NMIBC patients will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These positive results continue to support TARA-002’s potential in the NMIBC treatment landscape, and we look forward to finalizing a regulatory pathway for TARA-002 in BCG-Naïve patients," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "We remain on track to provide an update on the registrational BCG-Unresponsive patient cohort in the ADVANCED-2 trial in the first quarter of 2026 and expect to complete enrollment of this cohort in the second half of 2026."

"These encouraging TARA-002 results demonstrate meaningful and durable activity in BCG-Naïve NMIBC patients," said Mark Tyson, M.D., MPH, Vice Chair for Research and a Professor in the Department of Urology with the Mayo Clinic in Phoenix, Arizona, and ADVANCED-2 study investigator. "The clinically meaningful response rates at six and 12 months, coupled with a favorable safety and tolerability profile and simple administration that is even more streamlined than BCG, make TARA-002 a compelling potential treatment option in the BCG-Naïve setting."

Updated Interim Results

The dataset includes 31 BCG-Naïve patients who received at least 1 dose of TARA-002; 29 patients completed at least one response assessment and were evaluable for efficacy as of a November 7, 2025 data cutoff. Patients received an induction course of six weekly intravesical instillations of TARA-002, followed by a maintenance course of three weekly instillations every three months. Re-induction was permitted for eligible patients with residual CIS and/or recurrent high-grade Ta disease. Complete response (CR) rates at the six months and 12 months landmark time points include all participants who were either evaluable at that time point or had experienced disease progression or treatment failure prior to the scheduled visit.

The CR rate at any time was 72% (21/29).
The CR rate was 69% (18/26) at six months and 50% (7/14) at 12 months.
Among initial responders, 88% (14/16) maintained their response through six months and 100% (3/3) through 12 months.
Re-induction therapy successfully salvaged most initial non-responders, resulting in high conversion rates and durable responses: 80% (4/5) of re-induced patients converted to a CR at 6 months, and 100% (4/4) of those responders maintained their CR at 12 months.
Safety and Tolerability

The majority of treatment-related adverse events (TRAEs) were Grade 1 and transient with no Grade 3 or greater TRAEs as assessed by study investigators. No patients discontinued treatment due to TRAEs. The most commonly occurring TRAEs were dysuria (13%), fatigue (13%), and hematuria (6%).

Regulatory Update

The Company remains in ongoing dialogue with the U.S. Food and Drug Administration (FDA) on an expansion of the agreed upon registrational path forward for TARA-002 beyond the BCG-Unresponsive NMIBC patient population. The FDA has provided written feedback supporting a registrational design for a controlled trial in BCG-Naïve patients (who have never been exposed and those who have not received BCG within the last 24 months and are ineligible to receive BCG or contraindicated, cannot tolerate BCG, do not have access to BCG, or refuse BCG). The FDA has agreed that BCG is not required as a comparator and that intravesical chemotherapy is an acceptable comparator to TARA-002 in BCG-Naïve patients. The FDA also is aligned with the primary endpoint of the trial as the CR rate at month 6 with duration of response as a key secondary endpoint. The Company has engaged the FDA to determine how to include BCG-Exposed patients in its clinical trials of TARA-002, for whom no FDA-approved treatments are available and who have limited options to access investigational treatment through clinical trials.

About ADVANCED-2

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive (Cohort B N=75-100) or BCG-Naïve (Cohort A N=31). Trial subjects received an induction course, with or without a reinduction, of six weekly intravesical instillations of TARA-002, followed by a maintenance course of three weekly instillations every three months.

The Company remains on track to report interim results from approximately 25 six-month evaluable NMIBC patients from ADVANCED-2 with carcinoma in situ or CIS (± Ta/T1) who are BCG-Unresponsive in the first quarter of 2026 and expects to complete enrollment in this cohort in the second half of 2026.

Conference Call and Webcast

Protara will host a conference call and webcast today at 8:30 am ET to review the data reported this morning. The live event and accompanying slides can be accessed by visiting View Source, or via the Events and Presentations section of the Company’s website: View Source A replay of the webcast will be archived for a limited time following the event.

About TARA-002

TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil in Japan by Chugai Pharmaceutical Co., Ltd. Protara has successfully shown manufacturing comparability between TARA-002 and OK-432.

TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes with a mechanism of action that includes the activation of innate and adaptive immune pathways within the bladder wall. When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a pro-inflammatory response with release of cytokines such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma IL-6, IL-10, IL-12. TARA-002 also directly kills tumor cells and triggers a host immune response by inducing immunogenic cell death, which further enhances the antitumor immune response.

About Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle

(Press release, Protara Therapeutics, DEC 3, 2025, View Source [SID1234661107])

On December 3, 2025 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO (Free ESMO Whitepaper) Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-naïve patients with EGFR exon 20 mutant NCSLC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mini-oral presentation details:

Title: Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant
EGFR and HER2 Inhibitor, in Previously Treated NSCLC with
EGFR Atypical Mutations: Randomized Dose Optimization and
CNS Activity
Presentation Number: LBA15
Session Type and Title: Mini Oral session 1: Thoracic malignancies
Lecture Date and Time: Friday, December 5, 2025; 11:38 – 11:43 a.m. SGT

Proffered paper oral presentation details:

Title: Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant
EGFR and HER2 Inhibitor, in EGFR Exon 20 Mutant NSCLC:
Randomized Dose Optimization and CNS Activity
Presentation Number: LBA13
Session Type and Title: Proffered Paper session: Thoracic malignancies
Lecture Date and Time: Saturday, December 6, 2025; 10:02 – 10:12 a.m. SGT

Full late-breaking abstracts are available for public viewing via the ESMO (Free ESMO Whitepaper) Asia Congress website.

Conference Call and Webcast Details
In conjunction with the ESMO (Free ESMO Whitepaper) Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

(Press release, ORIC Pharmaceuticals, DEC 3, 2025, View Source [SID1234661105])